DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. was an American pharmaceutical company specializing in dermatology. Founded in 1991 by Canadian dermatologist and pharmaceutical executive D. Geoffrey Shulman, the company developed and commercialized treatments for skin conditions, with its most significant product being Levulan photodynamic therapy. Levulan used aminolevulinic acid as part of a photodynamic treatment approach and became a notable product in the development of topical photodynamic therapy in the United States. In 1999, Levulan became the first topical photodynamic therapy approved in the United States for the treatment of actinic keratosis, a common precancerous skin condition associated with cumulative sun exposure. The product represented DUSA's central contribution to dermatology: combining a pharmaceutical photosensitizing agent with controlled light exposure to target abnormal skin lesions. DUSA's activities therefore extended beyond conventional topical medicines and into a treatment modality requiring both a drug component and a clinical light-based procedure. The company also marketed Nicomide and expanded its dermatology portfolio through acquisition. In the first quarter of 2006, DUSA acquired Sirius Laboratories in a transaction valued at approximately $30 million. Sirius was a privately held specialty pharmaceutical company founded in 2000 by dermatologist Joel E. Bernstein. Its development work covered dermatological conditions including acne vulgaris and rosacea, giving DUSA access to additional specialty products and expertise. DUSA underwent a leadership transition in 2007. Robert F. Doman became chief executive officer in June of that year, while Shulman remained chairman of the board and took on the role of chief strategic officer. Shulman's responsibilities later changed because of serious illness. His employment agreement ended in December 2008 and was replaced by a part-time consulting arrangement, according to company filings cited in the company's historical account. In 2012, Caraco Pharmaceutical Laboratories, a subsidiary of Sun Pharmaceutical Industries, acquired DUSA Pharmaceuticals. The acquisition ended DUSA's existence as an independent pharmaceutical company, but its products continued to be marketed under the DUSA Dermatology name. As a result, DUSA is best understood today as a former corporate pharmaceutical company and continuing dermatology product identity within the Sun Pharmaceutical organization, rather than as an independently operating public company. Publicly documented information emphasizes its dermatology specialization, Levulan's regulatory significance, the Sirius Laboratories acquisition, and the company's eventual integration into Sun Pharma's broader business.

DUSA Pharmaceuticals was established in 1991 by D. Geoffrey Shulman, a Canadian dermatologist and pharmaceutical executive. It was organized as an American specialty pharmaceutical company with a focus on dermatology, an area in which Shulman's medical background shaped the company's product strategy. The company's principal development was Levulan photodynamic therapy. Levulan used aminolevulinic acid in combination with light-based treatment to address abnormal skin lesions. In 1999, it became the first topical photodynamic therapy approved in the United States for actinic keratosis. That regulatory milestone gave DUSA a distinctive position in dermatology because the treatment combined a pharmaceutical agent with a clinical photodynamic procedure rather than relying only on a conventional cream or oral medicine. DUSA's portfolio also included Nicomide. The company later broadened its activities through the acquisition of Sirius Laboratories during the first quarter of 2006. The transaction was valued at approximately $30 million. Sirius had been founded in 2000 by dermatologist Joel E. Bernstein and was a privately held specialty pharmaceutical company developing treatments for dermatological conditions such as acne vulgaris and rosacea. Leadership changed in June 2007, when Robert F. Doman was elected chief executive officer. Shulman continued as chairman of the board and assumed the position of chief strategic officer. The company's filings later described changes connected with Shulman's serious illness. His employment agreement was terminated in December 2008 and replaced by a part-time consulting arrangement. DUSA's independent corporate history ended in 2012, when Caraco Pharmaceutical Laboratories acquired the company. Caraco was a subsidiary of Sun Pharmaceutical Industries. Following the acquisition, DUSA's products continued to be marketed under the DUSA Dermatology name. Thus, the DUSA name survived as a dermatology-oriented product and business identity even though DUSA Pharmaceuticals no longer operated as an independent company. The available historical record centers on the development and approval of Levulan, the Sirius acquisition, management succession, and integration into Sun Pharma's corporate structure.

• 2012

  DUSA is acquired by Caraco

  [1]DUSA Pharmaceuticalsen.wikipedia.org

  Caraco Pharmaceutical Laboratories, a Sun Pharmaceutical subsidiary, acquired DUSA Pharmaceuticals. The products continued under the DUSA Dermatology name.

• 2008

  Shulman moves to consulting role

  [1]DUSA Pharmaceuticalsen.wikipedia.org

  After changes attributed in company filings to Shulman's serious illness, his employment agreement was replaced by a part-time consulting arrangement.

• 2007

  Robert F. Doman becomes CEO

  [1]DUSA Pharmaceuticalsen.wikipedia.org

  Robert F. Doman became chief executive officer, while Shulman remained chairman and became chief strategic officer.

• 2006

  Sirius Laboratories acquisition

  [1]DUSA Pharmaceuticalsen.wikipedia.org

  DUSA acquired Sirius Laboratories in a transaction valued at approximately $30 million, adding dermatology development activities involving acne vulgaris and rosacea.

• 1999

  Levulan receives U.S. approval for actinic keratosis

  [1]DUSA Pharmaceuticalsen.wikipedia.org

  Levulan became the first topical photodynamic therapy approved in the United States for actinic keratosis.

• 1991

  DUSA Pharmaceuticals is founded

  [1]DUSA Pharmaceuticalsen.wikipedia.org

  D. Geoffrey Shulman founded DUSA Pharmaceuticals as an American pharmaceutical company focused on dermatology.

A specialty dermatology pharmaceutical company centered on prescription skin treatments and photodynamic therapy, with Levulan as its defining product and technological contribution.

• Photodynamic therapy · 1999

  Levulan

  Levulan is DUSA's signature dermatology product and is based on aminolevulinic acid used in photodynamic therapy. The treatment combines a topical pharmaceutical agent with controlled light exposure to target abnormal skin lesions. In 1999, Levulan became the first topical photodynamic therapy approved in the United States for actinic keratosis, establishing the product as the company's principal regulatory and commercial milestone.

• Dermatological medicine

  Nicomide

  Nicomide was part of DUSA Pharmaceuticals' dermatology product portfolio. The available reference material identifies it as one of the company's products but does not provide sufficient detail here about its formulation, indications, launch date, or later commercial status.

• Dermatological medicines · 2006

  Sirius Laboratories dermatology products

  Through its 2006 acquisition of Sirius Laboratories, DUSA added access to specialty pharmaceutical development involving acne vulgaris and rosacea. The available material does not identify the individual products or their launch dates.

• 2012

  Sell DUSA Pharmaceuticals to Caraco Pharmaceutical LaboratoriesM&A

  Background

  DUSA Pharmaceuticals was acquired by Caraco Pharmaceutical Laboratories, a subsidiary of Sun Pharmaceutical Industries.

  Action taken

  Caraco completed the acquisition of DUSA Pharmaceuticals.

  Aftermath

  DUSA ceased to exist as an independent pharmaceutical company, while its products continued to be marketed under the DUSA Dermatology name.

  Source

• 2006

  Acquire Sirius LaboratoriesM&A

  Background

  DUSA sought to expand its specialty dermatology portfolio beyond its existing products. Sirius Laboratories was a privately held company founded by dermatologist Joel E. Bernstein with development work in acne vulgaris and rosacea.

  Action taken

  DUSA acquired Sirius Laboratories during the first quarter of 2006 in a transaction valued at approximately $30 million.

  Aftermath

  The acquisition broadened DUSA's dermatology-oriented development and product base.

  Transaction value. (First quarter of 2006)

  Source

• 2012

  DUSA is acquired by Caraco Pharmaceutical Laboratories[1]DUSA Pharmaceuticalsen.wikipedia.org

  M&A

  Caraco Pharmaceutical Laboratories, a subsidiary of Sun Pharmaceutical Industries, acquired DUSA Pharmaceuticals. DUSA's products subsequently continued to be marketed under the DUSA Dermatology name.

• 2007

  Robert F. Doman becomes chief executive officer[1]DUSA Pharmaceuticalsen.wikipedia.org

  Leadership change

  Robert F. Doman was elected chief executive officer. Founder D. Geoffrey Shulman remained chairman and became chief strategic officer.

• 2006

  DUSA acquires Sirius Laboratories[1]DUSA Pharmaceuticalsen.wikipedia.org

  M&A

  DUSA Pharmaceuticals acquired privately held Sirius Laboratories in a transaction valued at approximately $30 million, expanding its dermatology portfolio into areas including acne vulgaris and rosacea.

1. 1DUSA Pharmaceuticalsen.wikipedia.org